Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden

Medicine & Life Sciences

• Glycopyrrolate 100%
• Tiotropium Bromide 96%
• Sweden 63%
• Chronic Obstructive Pulmonary Disease 57%
• Cost-Benefit Analysis 55%
• Costs and Cost Analysis 24%
• Disease Progression 20%
• Cost Savings 14%
• Forced Expiratory Volume 13%
• Uncertainty 11%
• Placebos 8%
• Odds Ratio 8%
• Guidelines 8%
• Therapeutics 6%

Business & Economics

• Cost-effectiveness 90%
• Sweden 60%
• Progression 21%
• Time Horizon 21%
• Efficacy 20%
• Markov Model 18%
• Cost Estimates 12%
• Case Analysis 11%
• Cost Savings 9%
• Sensitivity Analysis 9%
• Uncertainty 6%
• Alternatives 5%
• United States of America 4%
• Costs 4%

Social Sciences

• Sweden 54%
• costs 36%
• utility value 15%
• savings 10%
• uncertainty 8%
• time 7%
• literature 4%